Genmab

	9/11 16:15 af Bulder	Er vi imponerede? Disease control, stable dsease og 2 partial responses. Det er nok i combo'erne at vi skal se noget der batter?
	9/11 16:12 af Bulder	Now we know that 100 mg is chosen dose for gen1046 :-)
	9/11 16:09 af E L	863 In vitro and in vivo studies establish DuoBody®-CD3xB7H4 as a novel drug candidate for the treatment of solid cancers (link)
	9/11 16:09 af E L	not that interesting for us
	9/11 16:06 af E L	786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data (link)
	9/11 16:05 af Bulder	Alt least favorable safety profile, but modest responses.
	9/11 16:04 af E L	516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial (link)
	9/11 16:02 af GeorgeBest	Conclusions DuoBody-CD40×4-1BB demonstrated biologic and early antitumor activity with a favorable safety profile in patients with advanced solid tumors. Expansion cohorts, including combination therapy with PD-1 inhibitors, are currently enrolling.
	9/11 15:59 af E L	493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors (link)
	9/11 15:52 af troldmanden	Ja ligner et af de targets hvor branchen godt kan finde på at lukke det meste ned. Det sker ind imellem
	9/11 15:50 af Sukkeralf	Lader til at være et svært target
	9/11 15:50 af Sukkeralf	Mon ikke Janssens DuoBody mod samme target ligeledes ryger i skralderen før eller siden - der har jo tidligere været clinical holds
	9/11 15:41 af GeorgeBest	Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target (link)
	9/11 15:40 af Bulder	They have removed the general link to the anstract publications. So something is not working over there.
	9/11 15:38 af Bulder	så der burde være expansion-data i hvert fald for dette studie.
	9/11 15:38 af Bulder	fordrev tiden med at kigge på titler igen. For gen1046 hedder den "Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4-1BB (GEN1046) trial"
	9/11 15:21 af Bulder	E L now we need your hacking skills.
	9/11 15:19 af Bulder	Funny, the ePoster site is working. But ePosters are not available before Friday. :-D
	9/11 15:13 af Bulder	It's always a bit of a jungle.
	9/11 15:12 af E L	yes, never understand why they make it so hard to find these abstracts! just post a simple working link ffs..
	9/11 15:08 af Bulder	... linket til sitc abstracts
	9/11 15:07 af Bulder	Får I også page not found når I klikker på linket?
	9/11 14:49 af Bulder	Nå, peak'en forleden på opjusteringen var forbigående. Hverdagen (voldgiftsusikkerheden) har meldt sig igen.
	9/11 14:49 af E L	the slides read 'Phase 2 trial of BNT311 as monotherapy and in combination with pembrolizumab in R/R metastatic NSCLC expected to start in Q4 2021'

	9/11 14:48 af E L	(link) slides
	9/11 14:28 af GeorgeBest	Yes agree
	9/11 14:27 af E L	after all, we have already seen that trial on (link)
	9/11 14:27 af E L	I think that may be a typo in their release? shouldn't that be the fourth quarter of 2021 instead of 2022.
	9/11 14:20 af GeorgeBest	BioNTech Q3 ude. GEN1046 fase 2 combo med Pembro startes i Q4. 2 PR opnået i GEN1042 (link)
	9/11 13:09 af Bulder	Linket igen (link)
	9/11 12:59 af Bulder	Iøvrigt giver artiklen også en forklaring på hvorfor det 3. boosterstik er en god idé, ikke kun for MS-patienter, men for alle.
	9/11 12:57 af Bulder	Det ser ud til at forklaringen ligger i den lave sc-dosis (som så skal gives oftere), som ikke slår så mange B-celler ihjel, som f.eks. ocrelizumab.
	9/11 12:55 af Bulder	I går var gentogen så venlig at linke til en artikel i Medscape, som fra Ectrims beretter, at ofa ikke i samme grad som ocrelizumab og rituximab mindsker effekten af covid-vacciner. Hvis man ikke allerede har gjort det, kan det anbefales at lade sig registrere og læse hele artiklen.
	9/11 12:17 af E L	the only revenue for Bolt Biotherapeutics seems to come from Genmab 'Revenue in 2021 was generated from services performed under the R&D collaboration with Genmab.' total revenue was $752.000. (link)
	9/11 12:03 af Plimsoller	God morgen :-)
	9/11 07:59 af Helge Larsen/PI-redaktør	Asien: Markeder i rødt oven på mandagens Fed-rapport (link)
	9/11 07:59 af Helge Larsen/PI-redaktør	God morgen. :-)
	9/11 02:44 af StockBull	Ja kun udsving på 46kr - ser også helst kursen svinger 2-3% i løbet af dagen med højere volumen
	8/11 18:47 af Bulder	SITC abstracts i morgen kl 14.
	8/11 16:59 af Don Joning	tak for gode svar, alle sammen, jeg kunne heller ikke få mit hoved omkring det. Man kunne måske håbe det er et godt salgsargument for at skifte eller vælge til Ofa :)
	8/11 16:58 af gentogen	(link)
	8/11 16:58 af gentogen	New data on COVID vaccination in multiple sclerosis (MS) patients has shown a reduced humoral response in patients treated with the anti-CD20 antibodies ocrelizumab or rituximab, but not in those receiving the similar product, ofatumumab.
	8/11 16:15 af GeorgeBest	Bispecific Antibodies For Cancer Market Shows Impressive Rise in the Industry Growth Rate, Players – Jounce Therapeutics, Affimed Therapeutics, Genmab, EMD Serono. (link)
	8/11 16:02 af E L	exactly, the vaccine is generally not effective for patients that are using drugs like ofatumumab ; so some patients do not want to take ofatumumab because they are worried their vaccine may not work, which is offcourse bad for ofa sales. Hopefully this regeneron drug can now also protect ofa users against covid
	8/11 16:02 af Sukkeralf	Enig med Bulder
	8/11 15:54 af Bulder	Det har været fremme at cd20-antistoffer (altså også ofa) hæmmer effekten af covid-vaccine. Regen-cov kan altså være et alternativ til vaccine for f.eks sklerose-patienter. Der er ikke tale om at ofa skal bruges mod covid. Sådan forstår jeg det.
	8/11 15:43 af Don Joning	jeg kan ikke forholde mig til den information EL, har du en holdning til det ? Hvordan kan Ofa indgå i Covid 19 bekæmpelse, kan det prissættes så det på nogen måde kan forsvares..?
	8/11 14:10 af E L	"These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised." more good news for patients on drugs like ofatumumab i guess
	8/11 14:10 af E L	New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 (link)
	8/11 13:45 af Helge Larsen/PI-redaktør	Aktier/middag: Vestas blæser C25 i grønt - Europa på kanten af rødt (link)